BioCentury on BioBusiness,
Emerging Company Profile
Complix says Alphabody technology offers super-stable protein drug scaffolds
Related tables, figures and sidebars
Complix: Scaffolds with a twist
Monday, September 6, 2010
N.V. believes the protein scaffolds created with its Alphabody
technology will have greater stability and diversity than therapeutics based on
other protein scaffolds. The resulting therapeutics could bind their targets
with greater affinity than other types of proteins, and the company expects
Alphabodies to be amenable to routes of administration other than injection.
The company was founded in 2008 based on the work of CSO
Ignace Lasters and CEO Mark Vaeck. This is Vaeck's third venture in the
next-generation protein space. He was previously CEO of Ablynx
N.V., which is developing Nanobody therapeutics, and of ActoGeniX
N.V., which is using genetically modified bacteria for oral delivery of
protein and peptide therapeutics.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]